Pronunciation: RYE–breh–vant
Generic name: amivantamab-vmjw
Dosage form: Intravenous infusion
Drug class: Miscellaneous antineoplastics

Medically reviewed by Melisa Puckey, BPharm. Last updated on Mar 6, 2024.

What is Rybrevant?

Rybrevant is a used to treat certain non-small cell lung cancers (NSCLC) that are advanced and have an abnormal "EGFR" gene. Rybrevant may help reduce the size of the non-small cell lung cancer and in some cases it may disappear.  Your doctor will test your cancer to check if it has the EGFR gene mutation.
Rybrevant works by blocking EGFR on the cancer cell which stops the tumors from growing, and Rybrevant also helps your immune system to identify cancer cells with EGFR and destroy them.

Rybrevant is from a group of medicines called targeted antibodies and is also called a bispecific EGF receptor-directed and MET receptor-directed antibody.

Rybrevant FDA approval was originally on the May 21, 2021. Rybrevant  (amivantamab-vmjw) is approved to be used in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. Rybrevant is also approved as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. 

Rybrevant side effects

Common Rybrevant side effects 

Common Rybrevant side effects may include a reaction during the injection, cough, shortness of breath, feeling very tired, rash, infection of the a skin around your nails, swelling anywhere in your body, nausea, vomiting, constipation, mouth sores, joint or muscle pain or abnormal blood tests.

Serious Rybrevant side effects 

Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Some side effects may occur during the injection. Tell your care provider if you feel nauseated, light-headed, short of breath, chilled or feverish, or if you have chest discomfort.

Rybrevant may cause serious side effects. Call your doctor at once if you have:

• eye pain or redness, itching, watery eyes, sensitivity to light;
• vision changes;
• dark floating spots in your field of vision (floaters);
• skin changes such as acne, itching, or dryness; or
• lung problems (may be similar to symptoms of your cancer) - new or worsening cough, fever, or shortness of breath.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

Infusion-Related Reactions (IRR): Interrupt infusion at the first sign of IRRs. Reduce infusion rate or permanently discontinue Rybrevant based on severity of reaction.

Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening lung symptoms indicative of ILD. In patients with suspected ILD/pneumonitis immediately withhold Rybrevant and permanently discontinue if ILD/pneumonitis is confirmed. 

Dermatologic Adverse Reactions: May cause rash including a type of dermatitis and toxic epidermal necrolysis (TEN). Withhold, dose reduce or permanently discontinue Rybrevant based on severity. Rybrevant can cause skin reactions. Avoid sunlight while you are receiving amivantamab and for 2 months after your last dose.

Ocular Toxicity: Promptly refer patients with worsening eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue medicine based on severity. 

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. 

Before taking this medicine

Tell your doctor if you have ever had lung problems other than cancer.

Pregnancy

Rybrevant may harm an unborn baby. Females who are able to become pregnant may need a pregnancy test to make sure you are not pregnant before treatmen. Use birth control while using this medicine and for at least 3 months after your last dose. Tell your doctor if you become pregnant or think you may be pregnant.

Breastfeeding

Do not breastfeed while using this medicine, and for at least 3 months after your last dose.

How will I receive Rybrevant?

Rybrevant is given as an infusion into a vein (intravenous infusion) by a healthcare provider, which takes several hours.

You may be given other medications to help prevent serious side effects or an allergic reaction. Keep using these medicines for as long as your doctor has prescribed.

You may need frequent vision exams.

May cause rash, itching, and dry skin. Use only alcohol-free cream or lotion to treat dry skin.

Rybrevant dosing information

Usual Adult Rybrevant Dose for Non-Small Cell Lung Cancer:

Weeks 1 to 4:
Less than 80 kg: 1050 mg IV once a week for 4 doses
At least 80 kg: 1400 mg IV once a week for 4 doses

Week 5 onwards:
Less than 80 kg: 1050 mg IV every 2 weeks
At least 80 kg: 1400 mg IV every 2 weeks

Duration of therapy: Until disease progression or unacceptable toxicity.

Comments:
The dose should be based on baseline body weight; dose adjustments are not needed for subsequent body weight changes.
The initial dose should be administered as a split infusion in Week 1, on Day 1 and Day 2.
Before the initial infusion on Week 1 (Days 1 and 2), premedication should be administered to reduce the risk of infusion-related reactions.
-An antihistamine and antipyretic should be administered before all infusions.
-A glucocorticoid is required for Week 1 (Days 1 and 2) doses only and should be used as needed for subsequent infusions.
The initial infusion rate may be increased to the subsequent infusion rate after 2 hours without an infusion-related reaction.

Rybrevant is available as a single-dose vial 350 mg/7 mL (50 mg/mL) solution.

For more detailed information on dosage, including infusion rates, click the link below.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your next injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while taking Rybrevant?

Rybrevant can cause skin reactions. Avoid sunlight and tanning beds during treatment and for 2 months after your last dose. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

If you have problems with your eyes, avoid wearing contact lenses until an eye doctor can check your symptoms.

What other drugs will affect Rybrevant?

Other drugs may affect Rybrevant, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Rybrevant Package Insert 

Review the Rybrevant Package Insert for more detailed information about this medicine. Discuss any medical questions with your doctor or other health care provider. This is not all the information you need to know about this medicine for safe and effective use, and it does not take the place of talking to your doctor about your treatment.

Ingredients

Active ingredient: amivantamab-vmjw
Inactive ingredients: EDTA disodium salt dihydrate, L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 80, sucrose, and water for injection.

Storage 

Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze.

Company

Manufactured by: Janssen Biotech, Inc. Horsham, PA 19044, USA U.S. License Number 1864 

Popular FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer